Neurocrine Biosciences | NBIX - Market Capitalization



Neurocrine Biosciences reported $14.32B in Market Capitalization this September of 2025, considering the latest stock price and the number of outstanding shares.


Market Capitalization Change Date
AbbVie USD 327.88B 42.76B Jun/2025
Acadia Pharmaceuticals USD 3.61B 840M Jun/2025
Agios Pharmaceuticals USD 1.93B 234M Jun/2025
ALKERMES USD 4.72B 725M Jun/2025
Alnylam Pharmaceuticals USD 42.52B 7.39B Jun/2025
Amgen USD 150.13B 17.37B Jun/2025
Biogen USD 18.41B 1.62B Jun/2025
BioMarin Pharmaceutical USD 10.54B 3.01B Jun/2025
Cytokinetics USD 3.95B 846M Jun/2025
Dynavax Technologies USD 1.19B 421M Jun/2025
Gilead Sciences USD 137.91B 1.77B Jun/2025
Halozyme Therapeutics USD 6.41B 1.47B Jun/2025
Incyte USD 13.18B 1.46B Jun/2025
Ionis Pharmaceuticals USD 6.29B 1.49B Jun/2025
Neurocrine Biosciences USD 12.44B 1.5B Jun/2025
Pfizer USD 137.53B 6.19B Jun/2025
Prothena USD 441M 114M Sep/2025
Regeneron Pharmaceuticals USD 55.87B 13.47B Jun/2025
Repligen USD 6.99B 160M Jun/2025
Sarepta Therapeutics USD 1.68B 4.51B Jun/2025
Teva Pharmaceutical Industries ILS 65.36B 1.34B Jun/2025
Ultragenyx Pharmaceutical USD 3.44B 38M Jun/2025
Vertex Pharmaceuticals USD 114.33B 10.31B Jun/2025